About
MIMS® creates a drainage channel to reduce IOP in Glaucoma patients, ensuring a long-lasting safe and controlled fluid flow, no stitches, eye-patch, implant or stent. It is designed to reduce the caring costs of Glaucomatous patients’ through simplicity, low cost, fewer post-surgical complications and less hospitalization. • A novel Glaucoma treatment • Leaves nothing behind (stent-less) thus lowering the risk of complications • Can be easily combined with Cataract surgery • Medication-sparing which improves patients' quality of life
Tags
Total Employees
10
Current headcount
Performance
Company Timeline
No timeline data for this period
Score Breakdown
30Traction
10Team
30Visibility
25Profile
60Community
0Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Sanoculis do?
MIMS® creates a drainage channel to reduce IOP in Glaucoma patients, ensuring a long-lasting safe and controlled fluid flow, no stitches, eye-patch, implant or stent. It is designed to reduce the caring costs of Glaucomatous patients’ through simplicity, low cost, fewer post-surgical complications and less hospitalization. • A novel Glaucoma treatment • Leaves nothing behind (stent-less) thus lowering the risk of complications • Can be easily combined with Cataract surgery • Medication-sparing w…
When was Sanoculis founded?
Sanoculis was founded in 2012.
What industry does Sanoculis operate in?
Sanoculis operates in Healthcare.
How many employees does Sanoculis have?
Sanoculis has approximately 10 people on record.